Levonorgestrel And Ethinyl Estradiol Tablet
Product Images NDC 68462-637

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Levonorgestrel And Ethinyl Estradiol (NDC 68462-637). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Fig-1 (Fig 1)

Fig-1 (Fig 1)
FDA Label Image

Fig-2 (Fig 2)

Fig-2 (Fig 2)
FDA Label Image

Fig-3 (Fig 3)

Fig-3 (Fig 3)
FDA Label Image

Fig-4 (Fig 4)

Fig-4 (Fig 4)
This appears to be a graph or chart showing the percentage of subjects who experienced bleeding or spotting while using a certain type of birth control pill pack. The text indicates that bleeding required sanitary protection, while spotting only did not. The graph includes percentages ranging from 0 to 100 and numerical values along the x-axis. The quality is not sufficient to make out all the details of the graph or the accompanying text.*
FDA Label Image

Fig-5 (Fig 5)

Fig-5 (Fig 5)
This is a table with numbers showing the amount of days each subject took a pill pack for a clinical trial. The N indicates the number of subjects who completed the full 28-day course. No further information is available.*
FDA Label Image
Gkenmark Logo
FDA Label Image

Levonorgestrel Structure And Ethinyl Estradiol Structure (Image 01)

Levonorgestrel Structure And Ethinyl Estradiol Structure (Image 01)
Levonorgestrel and Ethinyl Estradiol are two chemicals with molecular weights of 312.45 g/mol and 296.40 g/mol respectively.*
FDA Label Image

Glenmark Logo (Image 02)

Glenmark Logo (Image 02)
FDA Label Image

Image 04

Image 04
The text is describing a carton of Levonorgestrel and Ethinyl Estradiol tablets, USP. Each tablet contains 0.09 mg levonorgestrel and 0.02 mg ethinyl estradiol, USP. The usual dosage is one tablet daily without any tabletree inerval. The carton contains one package insert, three pouches, and three blisters each containing 28 tablets. The product is manufactured by Glenmark Pharmaceuticals Limited and is intended to prevent pregnancy but does not protect against HIV infection and other sexually transmitted diseases. The carton needs to be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F) and should be protected from light.*
FDA Label Image

Image 05

Image 05
FDA Label Image

Precentage Of Subjects Reporting Bleeding Or Spotting (Image 08)

Precentage Of Subjects Reporting Bleeding Or Spotting (Image 08)
This is a description of the percentage of subjects experiencing bleeding and spotting while taking birth control pills. The data is broken down by pill pack and numbered days. "N" represents the number of subjects with 20 days of data. Bleeding required sanitary protection, while spotting only did not require protection.*
FDA Label Image

Precentage Of Subjects Reporting Greater Than Or Equal (Image 09)

Precentage Of Subjects Reporting Greater Than Or Equal (Image 09)
FDA Label Image

Img-1 (Img 1)

Img-1 (Img 1)
This is a description of Levonorgestrel and Ethinyl Estradiol Tablets, with a dosage of 0.09 mg/0.02 mg. The text includes a warning to keep the medication out of the reach of children.*
FDA Label Image

Img-2 (Img 2)

Img-2 (Img 2)
The text contains information about a medication called Levonorgestrel and Ethinyl Estradiol Tablets USP with a dosage of 0.09 mg/0.02 mg. There is also a warning to keep the medication out of reach of children. Therefore, it can be inferred that the text represents the packaging or label of the medicine.*
FDA Label Image

Laminate

Laminate
This is a medication package of Levonorgestrel and Ethinyl Estradiol Tablets, USP manufactured by Glenmark Pharmaceuticals in India and manufactured for Glenmark Pharmaceuticals Inc. in the USA. Each blister contains 28 tablets and also includes a brief summary patient package insert, detailed patient labeling, a set of labels for use with the blister, and a product information sheet. The product is intended to prevent pregnancy, but it does not protect against HIV infection and other sexually transmitted diseases. The usual dosage is one tablet daily without any tablet-free interval, and the package must be kept at 20°C to 25°C to protect from light, with excursions permitted between 10°C to 30°C. It is not recommended for children, and the package does not feature child-resistant packaging.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.